Belapectin is under clinical development by Galectin Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Belapectin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Belapectin (GR-MD-02) is under development for the treatment of NASH with advanced fibrosis, liver fibrosis and decompensated liver cirrhosis, kidney fibrosis, cardiovascular fibrosis, pulmonary arterial hypertension, arrhythmias, metastatic melanoma, lung fibrosis, prostate cancer, sarcomas, breast cancer, head and neck cancer squamous cell carcinoma, non-small cell lung cancer and portal hypertension. It is administered through intravenous route and targets galectin-3. It is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer that is comprised predominantly of galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. The drug candidate is developed based on the carbohydrate technology. It is a new chemical entity. It was also under development for the treatment of diabetic nephropathy, moderate to severe plaque psoriasis and severe atopic dermatitis.
Galectin Therapeutics overview
Galectin Therapeutics is a biotechnology company. The company products includes for fibrosis, cancer immunotherapy, plaque psoriasis, and oral galectin-3 inhibitors. It discovers, develops and commercializes therapies for fibrotic disease and cancer. Galectin Therapeutics also offer products such as GR-MD-02, GM-CT-01. Its GR-MD-02 is a drug candidate used for treating fibrotic liver disease. Its GM-CT-01 is a vaccine used to treat patients with advanced melanoma, a deadly skin cancer. Galectin The company provides research, study of science of galectin proteins. Its products are used to treat fibrosis, galectin effects on liver fibrosis, lung fibrosis and cancer immunotherapy. Galectin Therapeutics is headquartered in Norcross, Georgia, the US.
For a complete picture of Belapectin’s drug-specific PTSR and LoA scores, buy the report here.